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BACKGROUND: Schizophrenia and bipolar disorder share genetic liability, and some structural brain abnormalities
are common to both conditions. First-degree relatives of patients with schizophrenia (FDRs-SZ) show similar brain
abnormalities to patients, albeit with smaller effect sizes. Imaging ﬁndings in ﬁrst-degree relatives of patients with
bipolar disorder (FDRs-BD) have been inconsistent in the past, but recent studies report regionally greater
volumes compared with control subjects.
METHODS:Weperformedameta-analysis of global andsubcortical brainmeasuresof 6008 individuals (1228FDRs-SZ,
852 FDRs-BD, 2246 control subjects, 1016 patients with schizophrenia, 666 patients with bipolar disorder) from 34
schizophrenia and/or bipolar disorder family cohorts with standardized methods. Analyses were repeated with a
correction for intracranial volume (ICV) and for thepresenceof anypsychopathology in the relatives andcontrol subjects.
RESULTS: FDRs-BD had signiﬁcantly larger ICV (d = 10.16, q , .05 corrected), whereas FDRs-SZ showed smaller
thalamic volumes than control subjects (d = 20.12, q , .05 corrected). ICV explained the enlargements in the brain
measures in FDRs-BD. In FDRs-SZ, after correction for ICV, total brain, cortical gray matter, cerebral white matter,
cerebellar gray and white matter, and thalamus volumes were signiﬁcantly smaller; the cortex was thinner (d
, 20.09, q , .05 corrected); and third ventricle was larger (d = 10.15, q , .05 corrected). The ﬁndings were not
explained by psychopathology in the relatives or control subjects.
CONCLUSIONS: Despite shared genetic liability, FDRs-SZ and FDRs-BD show a differential pattern of structural
brain abnormalities, speciﬁcally a divergent effect in ICV. This may imply that the neurodevelopmental trajectories
leading to brain anomalies in schizophrenia or bipolar disorder are distinct.
Keywords: Bipolar disorder, Familial risk, Imaging, Meta-analysis, Neurodevelopment, Schizophrenia
https://doi.org/10.1016/j.biopsych.2019.03.985ª 2019 Society of Biological Psychiatry. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
545
ISSN: 0006-3223 Biological Psychiatry October 1, 2019; 86:545–556 www.sobp.org/journal
Brain Structure in Bipolar and Schizophrenia Relatives
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50 YearsSchizophrenia and bipolar disorder are highly heritable dis-
orders with partially overlapping symptoms and a genetic
correlation (rg) of 0.60–0.68 (1–3). Both disorders are char-
acterized by structural brain abnormalities, with smaller total
brain and hippocampal volumes, on average, and larger
ventricular volumes. These are among the most consistent
and robust structural ﬁndings, albeit with smaller effect sizes
in patients with bipolar disorder (4–12). On one hand, the
shared genetic liability between schizophrenia and bipolar
disorder (1–3) is partly reﬂected in the brain by overlapping
ﬁndings of smaller white matter volumes and common areas
of thinner cortex, suggesting that the disorders share genetic
(possibly neurodevelopmental) roots (13). On the other hand,
disease-speciﬁc brain abnormalities were also reported in the
same twin study; genetic liability for schizophrenia was
associated with thicker right parietal cortex, whereas genetic
liability for bipolar disorder was associated with larger intra-
cranial volume (ICV) (13).
Family members of patients can represent individuals at
familial risk for the disorder who do not themselves have
confounds, such as medication or illness duration, and can
therefore provide unique insight into the effect of familial risk
for the disorder on the brain. Multiple imaging studies have
investigated individuals at high familial risk for schizophrenia
and/or bipolar disorder, but results of these often small studies
have been variable. First-degree relatives of patients with
schizophrenia (FDRs-SZ) tend to show smaller brain volumes
and larger ventricle volumes compared with control subjects
(14,15). In contrast, ﬁrst-degree relatives of patients with bi-
polar disorder (FDRs-BD) show regionally larger volumes
(16–26). Many of these schizophrenia and bipolar disorder
family studies grouped all FDRs together regardless of kinship.
It remains unclear whether structural brain abnormalities in
high-risk individuals are consistent across FDRs, or whether
they vary depending on the generational relationship with the
proband. In addition, a few studies compared brain structure
between FDRs-BD and FDRs-SZ directly, usually in cohorts of
modest sample sizes (9,13,27–30). These studies showed
brain abnormalities both speciﬁc and overlapping for FDRs-SZ
and FDRs-BD; if anything, ﬁndings were more pronounced in
FDRs-SZ than FDRs-BD.
Large-scale multicenter studies offer increased power and
generalizability to evaluate the pattern and extent of brain
variation in FDRs-BD and FDRs-SZ. Through the Enhancing
Neuro Imaging Genetics Through Meta Analysis (ENIGMA)-
Relatives Working Group, we have performed meta-analyses
of magnetic resonance imaging data sets consisting of
FDRs-SZ and/or FDRs-BD, probands, and matched control
participants on harmonized global and subcortical brain mea-
sures. For each disorder, relatives were analyzed as a group as
well as per relative type, i.e., monozygotic co-twins, dizygotic
co-twins, offspring, siblings, and parents. To investigate po-
tential confounders, analyses were performed both with and
without correction for ICV and with and without a correction for
having a psychiatric diagnosis in the relatives and control
subjects. The latter correction was performed by 1) adding a
single dummy variable coding for the presence of any psy-
chiatric diagnosis and 2) by comparing only the healthy rela-
tives with the healthy control subjects. We hypothesized that546 Biological Psychiatry October 1, 2019; 86:545–556 www.sobp.orgFDRs-SZ (as a group) would exhibit a pattern of brain vol-
ume abnormalities similar to patterns observed in patients, but
with smaller effect sizes. Based on dissimilarities in the litera-
ture between FDRs-SZ and FDRs-BD, we expected divergent
effect sizes. Furthermore, we explored the pattern and extent
of brain volume abnormalities per relative type.
METHODS AND MATERIALS
Study Samples
This study included 6008 participants from 34 family cohorts.
In total, 1228 FDRs-SZ (49 monozygotic co-twins, 62 dizygotic
co-twins, 171 offspring, 842 siblings, 104 parents), 852 FDRs-BD
(41 monozygotic co-twins, 48 dizygotic co-twins, 443 offspring,
302 siblings, 18 parents), 2246 control subjects, 1016 patients
with schizophrenia, and 666 patients with bipolar disorder were
included (Tables 1 and 2). All cohorts included their own control
participants. Control subjects did not have a family history of
schizophrenia or bipolar disorder. FDRs-SZ or FDRs-BD are
deﬁned by having a ﬁrst-degree family member with schizo-
phrenia or bipolar disorder, respectively, and not having experi-
enced (hypo)mania and/or psychosis themselves. Several
cohorts allowed FDRs-SZ, FDRs-BD, or control subjects to have
psychiatric diagnoses other than schizophrenia or bipolar disor-
der (Tables 1 and 2). Demographic characteristics for each
cohort and their inclusion criteria are summarized in Tables 1
and 2 and Supplemental Table S1. All study centers obtained
approval from their respective medical ethics committee for
research following the Declaration of Helsinki. Informed consent
was obtained from all participants (and/or parent guardians in
the case of minors).
Image Acquisition and Processing
Structural T1-weighted brain magnetic resonance imaging
scans were acquired at each research center (see
Supplemental Table S2 for acquisition parameters of each
cohort). Cortical and subcortical reconstruction and volumetric
segmentations were performed with the FreeSurfer pipeline
(see Table S2 for FreeSurfer version and operating system
used in each cohort) (http://surfer.nmr.mgh.harvard.edu/fswiki/
recon-all/) (31). The resulting segmentations were quality
checked according to the ENIGMA quality control protocol for
subcortical volumes (http://enigma.ini.usc.edu/protocols/
imaging-protocols/). Global brain measures (i.e., ICV [esti-
mated Total Intracranial Volume from FreeSurfer], total brain
[including cerebellum, excluding brainstem], cortical gray
matter, cerebral white matter, cerebellar gray and white matter,
third and lateral ventricle volume, surface area, and mean
cortical thickness) and subcortical volumes (i.e., thalamus,
caudate, putamen, pallidum, hippocampus, amygdala, and
accumbens) were extracted from individual images (32,33).
Statistical Meta-analyses
All statistical analyses were performed using R (http://www.r-
project.org). Linear mixed model analyses were performed
within each cohort for bipolar disorder and schizophrenia
separately, comparing relatives (per relative type) with control
subjects and, if present, patients with control subjects, while
taking family relatedness into account (http://CRAN.R-project./journal
Table 1. Sample Demographics Bipolar Disorder Family Cohorts
Sample
Controls Cases
Relatives
Total MZ Co-twins DZ Co-twins Offspring Siblings Parents
n M/F Age
Other Diagnoses
(Y/N) n M/F Age
Total
N n M/F Age
Other
Diagnoses
(Y/N) n M/F Age
Other
Diagnoses
(Y/N) n M/F Age
Other
Diagnoses
(Y/N) n M/F Age
Other
Diagnoses
(Y/N) n M/F Age
Other
Diagnoses
(Y/N)
BPO_FLB 7 3/4 12.9 0/7 9 5/4 13.3 22 — — 22 10/12 10.0 0/22 — —
Cardiff 79 28/51 39.8 0/79 120 42/78 41.9 33 — — — 33 13/20 45.9 2/31 —
CliNG-BDa 19 6/13 30.9 0/19 — 19 — — 11 4/7 23.4 0/11 8 2/6 43.8 0/8 —
DEU 29 11/18 33.1 0/29 27 10/17 36.3 23 — — 6 2/4 21.7 0/6 17 9/8 34.8 0/17 —
EGEU 33 13/20 33.6 0/33 27 16/11 36.7 27 — — — 27 10/17 34.5 0/27 —
ENBD_UT 36 13/23 34.8 0/36 72 23/49 36.9 52 — — — 52 10/42 44.3 17/35 —
HHR 42 17/25 21.9 0/42 8 2/6 23.3 52 — — 52 18/34 19.5 14/38 — —
IDIBAPSa 53 21/32 12.3 12/41 — 61 — — 61 31/30 12.3 27/34 — —
IoP-BD 39 9/30 35.4 9/30 34 15/19 40.6 17 11 2/9 43.5 6/5 6 2/4 42.4 0/6 — — —
MFS-BDa 54 25/29 40.2 0/54 38 15/23 41.0 41 — — — 23 11/12 42.9 0/23 18 6/12 57.6 0/18
MooDS-BDa 63 25/38 30.3 0/63 — 63 — — 53 18/35 29.2 0/53 10 7/3 36.6 0/10 —
MSSM 52 25/27 35.2 0/52 41 21/20 44.3 50 — — 27 14/13 24.9 15/12 23 12/11 44.2 8/15 —
Olin 68 25/43 32.2 7/61 108 34/74 34.5 78 — — — 78 30/48 32.0 21/57 —
PHHR 18 7/11 23.0 0/18 8 3/5 24.0 26 — — 26 10/16 19.9 6/20 — —
STAR-BDa 114 55/59 48.8 42/72 53 19/34 49.2 38 16 6/10 49.2 3/13 22 10/12 50.8 6/16 — — —
SydneyBipolarGroup 117 54/63 22.2 30/87 59 17/42 25.1 150 — — 119 53/66 19.2 58/61 31 12/19 22.6 21/10 —
UMCU-BD Twinsa 129 55/74 39.2 4/125 62 19/43 40.3 34 14 4/10 38.2 6/8 20 8/12 44.3 4/16 — — —
UMCU-DBSOSa 40 21/19 12.7 7/33 — 66 — — 66 37/29 14.7 31/35 — —
DZ, dizygotic; F, female; M, male; MZ, monozygotic; N, no; Y, yes.
BPO_FLB, Bipolar Offspring - Fronto-Limbic; Cardiff, Cardiff University; CliNG-BD, Clinical Neuroscience Goettingen- Bipolar Disorder; DEU, Dokuz Eylul University; EGEU, Ege University;
ENBD_UT, Endophenotypes of Bipolar Disorder - University of Texas; HHR, Halifax High Risk Study; IDIBAPS, August Pi i Sunyer Biomedical Research Institute; IoP-BD, Institute of Psychiatry
- Bipolar Disorder Twin Study; MFS-BD, Maudsley Family Study - Bipolar Disorder; MooDS-BD, Systematic Investigation of the Molecular Causes of Major Mood Disorders and Schizophrenia
- Bipolar Disorder; MSSM, Mount Sinai School of Medicine; Olin, Olin Neuropsychiatry Research Center; PHHR, Prague High Risk Study; STAR-BD, Schizophrenia and Bipolar Twin Study in
Sweden - Bipolar Disorder; SydneyBipolarGroup, The Sydney Bipolar Kids and Sibs Study; UMCU-BD Twins, University Medical Center Utrecht - Bipolar Disorder Twin Study; UMCU-DBSOS,
University Medical Center Utrecht - Dutch Bipolar and Schizophrenia Offspring Study.
aOverlapping control subjects with schizophrenia sample from the same site, i.e., with CliNG-SZ (n = 10), IDIBAPS (n = 53), MFS-SZ (n = 54), MooDS-SZ (n = 36), STAR-SZ (n = 100), UMCU-
UTWINS (n = 27), UMCU-DBSOS (n = 40).
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Table 2. Sample Demographics Schizophrenia Family Cohorts
Sample
Controls Cases
Relatives
Total MZ Co-twins DZ Co-twins Offspring Siblings Parents
n M/F Age
Other
Diagnoses
(Y/N) n M/F Age
Total
N n M/F Age
Other
Diagnoses
(Y/N) n M/F Age
Other
Diagnoses
(Y/N) n M/F Age
Other
Diagnoses
(Y/N) n M/F Age
Other
Diagnoses
(Y/N) n M/F Age
Other
Diagnoses
(Y/N)
C_SFS 23 11/12 40.2 7/16 25 13/12 40.8 23 — — — 13 7/6 32.5 4/9 10 1/9 54.6 3/7
CliNG-SZa 20 11/9 35.7 0/20 — 20 — — 6 3/3 26.7 0/6 7 5/2 28.4 0/7 7 3/4 51.9 0/7
EHRS 89 44/45 21.0 0/89 31 19/12 21.8 90 — — 57 26/31 20.9 0/57 33 18/15 21.8 0/33 —
HUBIN 102 69/33 41.9 29/73 103 77/26 41.2 33 — — — 33 23/10 39.4 8/25 —
IDIBAPSa 53 21/32 12.3 12/41 — 37 — — 37 22/15 11.0 18/19 — —
IoP-SZ 67 35/32 40.9 7/60 54 39/15 34.7 18 14 7/7 31.0 6/8 4 1/3 40.0 1/3 — — —
LIBD 364 163/201 32.4 3/361 215 164/51 35.3 242 — — — 242 100/142 36.2 83/159 —
Maastricht-
GROUP
87 33/54 30.8 14/73 87 59/28 28.2 95 — — — 95 49/46 29.5 19/76 —
MFS-SZa 54 25/29 40.2 0/54 42 31/11 36.4 56 — — — 20 10/10 36.4 0/20 36 11/25 56.6 0/36
MooDS-SZa 65 26/39 30.6 0/65 — 63 — — 31 10/21 26.5 0/31 25 12/13 30.2 0/25 7 2/5 49.7 0/7
NU 92 51/41 31.9 7/85 108 74/34 34.2 83 — — — 83 29/54 21.1 45/38 —
STAR-SZa 104 49/55 48.9 22/82 49 28/21 49.5 48 15 9/6 41.9 0/15 33 17/16 52.3 0/33 — — —
UMCG-GROUP 37 16/21 34.0 0/37 — 45 — — — 45 22/23 30.9 0/45 —
UMCU-DBSOSa 40 21/19 12.7 7/33 — 40 — — 40 12/28 13.7 24/16 — —
UMCU-GROUP 167 83/84 27.7 13/154 162 130/32 27.0 201 — — — 201 95/106 27.7 52/149 —
UMCU-Parents 41 14/27 52.8 0/41 — 44 — — — — 44 13/31 52.9 11/33
UMCU-UTWINSa 184 84/100 31.8 17/167 56 33/23 35.6 45 20 12/8 36.0 11/9 25 17/8 37.8 5/20 — — —
UNIBA 78 52/26 31.4 0/78 84 58/26 33.3 45 — — — 45 23/22 33.4 4/41 —
DZ, dizygotic; F, female; M, male; MZ, monozygotic; N, no; Y, yes.
C_SFS, Calgary Schizophrenia Family Study; CliNG-SZ, Clinical Neuroscience Goettingen - Schizophrenia; EHRS, Edinburgh High Risk Study; HUBIN, Human Brain Informatics; IDIBAPS,
August Pi i Sunyer Biomedical Research Institute; IoP-SZ, Institute of Psychiatry - Schizophrenia Twin Study; LIBD, Lieber Institute for Brain Development; Maastricht-GROUP, Maastricht -
Genetic Risk and Outcome of Psychosis; MFS-SZ, Maudsley Family Study - Schizophrenia; MooDS-SZ, Systematic Investigation of the Molecular Causes of Major Mood Disorders and
Schizophrenia - Schizophrenia; NU, Northwestern University; STAR-SZ, Schizophrenia and Bipolar Twin Study in Sweden - Schizophrenia; UMCG-GROUP, University Medical Center
Groningen - Genetic Risk and Outcome of Psychosis; UMCU-DBSOS, University Medical Center Utrecht - Dutch Bipolar and Schizophrenia Offspring Study; UMCU-GROUP, University
Medical Center Utrecht - Genetic Risk and Outcome of Psychosis; UMCU-Parents, University Medical Center Utrecht - Parents Study; UMCU-UTWINS, University Medical Center
Utrecht - Utrecht Twin Schizophrenia Studies; UNIBA, University of Bari “Aldo Moro.”
aOverlapping control subjects with bipolar sample from the same site, i.e., with CliNG-BD (n = 10), IDIBAPS (n = 53), MFS-BD (n = 54), MooDS-BD (n = 36), STAR-BD (n = 100), UMCU-BD
twins (n = 27), UMCU-DBSOS (n = 40).
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50 Yearsorg/package=nlme) (34). Given known age and sex effects on
brain measures, we included centered age, age squared, and
sex as covariates. Brain measures were corrected for lithium
use at time of scan (yes/no) in patients with bipolar disorder
only. Analysis of multiscanner studies included binary dummy
covariates for n21 scanners. Cohen’s d effect sizes and 95%
conﬁdence intervals were calculated within each cohort
separately and pooled per disorder for each relative type, for all
relatives, and for patients as a group, using an inverse
variance-weighted random-effects meta-analysis. All random-
effects models were ﬁtted using the restricted maximum like-
lihood method. False discovery rate (q , .05) thresholding
across all phenotypes was used to control for multiple com-
parisons for each pairwise analysis between relatives, patients,
and control subjects or between the different relative types
(35). Analyses were performed locally by the research center
that contributed the cohort, using codes created within the
ENIGMA-Relatives Working Group (scripts available on
request). The focus of this study is on ﬁrst-degree relatives, but
patient effects were also computed to show that the effects in
patients are in line with earlier work (4–12). Effect sizes were
statistically compared between FDRs-BD and FDRs-SZ,
FDRs-BD and patients with bipolar disorder, and FDRs-SZ
and patients with schizophrenia, and between the different
relative types within one disorder (Supplemental Methods). The
latter analysis was performed only when more than one cohort
was included per relative type.
The regional speciﬁcity of the ﬁndings was examined by
repeating the analyses of the global brain measures and
subcortical volumes with ICV added as a covariate. In addition,
we repeated the analyses to investigate the effect of psycho-
pathology in the relatives and control subjects using two
different approaches. First, we added a single dummy variable
for relatives and control subjects with a DSM “No diagnosis” or
ICD-9 code V71.09 (other diagnosis = 1, V71.09 = 0). Second,
we compared healthy relatives with healthy control subjects.
Finally, effects of age were examined using meta-regressions.
RESULTS
Patients
Effects in patients with schizophrenia and bipolar disorder
were not the main focus of this study. In short, a thinner cortex
and smaller thalamus volume were found in patients with bi-
polar disorder (d , 20.33, q , .05 corrected); in patients with
schizophrenia, smaller volumes of total brain, cortical gray
matter, cerebral white matter, cerebellar gray and white matter,
thalamus, hippocampus, amygdala, and accumbens, thinner
cortex (d , 20.18, q , .05 corrected), and larger volumes of
the lateral ventricles, third ventricle, caudate, pallidum, and
putamen (d . 10.16, q , .05 corrected) were found. The
ﬁndings are summarized in Figures 1 and 2, Supplemental
Figure S1i–xvii, and Supplemental Tables S3 and S4.
FDRs-BD and FDRs-SZ vs. Control Subjects
FDRs-BD had signiﬁcantly larger ICVs than control subjects
(d =10.16, q, .05 corrected) (Figures 1A and 2A, Supplemental
Figure S1i–xvii, and Supplemental Table S3). FDRs-SZ had
signiﬁcantly smaller thalamic volume than control subjectsBiological Ps(d =20.12, q, .05 corrected) (Figures 1A and 2A, Supplemental
Figure S1i–xvii, and Supplemental Table S3). When comparing
the effect sizes of FDRs-BD and FDRs-SZ directly, FDRs-BD had
signiﬁcantly larger ICV, surface area, total brain, cortical gray
matter, cerebral white matter, cerebellar gray matter, thalamus,
andaccumbensvolumesand smaller third ventricle volumes than
FDRs-SZ (q , .05 corrected) (Supplemental Table S3). For all
nominally signiﬁcant effect sizes (p , .05 uncorrected, 2-tailed)
and comparisons, see Supplemental Table S3.
Regional Speciﬁcity of Findings: Correction for ICV
When controlling for ICV, there were no signiﬁcant differences
in brain measures between FDRs-BD and control subjects
(Figures 1B and 2B and Supplemental Table S4). In contrast, in
FDRs-SZ, total brain, cortical gray matter, cerebral white
matter, cerebellar gray and white matter, and thalamus vol-
umes were signiﬁcantly smaller, cortex was thinner (d,20.09,
q , .05 corrected), and third ventricle was larger (d = 10.15, q
, .05 corrected) than in control subjects (Figures 1B and 2B
and Supplemental Table S4). FDRs-BD had signiﬁcantly
larger total brain, cortical, and cerebellar gray matter volumes
and smaller third ventricle volumes than FDRs-SZ (q , .05
corrected) (Supplemental Table S4).
First-Degree Relatives Subtype Analyses
None of the effect sizes comparing FDRs-BD and FDRs-SZ
subtypes with control subjects survived correction for multi-
ple comparisons. Direct comparison between the different
relative subtypes showed some signiﬁcant differences be-
tween groups; see Supplemental Tables S7 and S8,
Supplemental Figure S1i–xvii and Supplemental Results.
Psychopathology in Relatives
Psychiatric diagnoses other than bipolar disorder or a psy-
chotic disorder were present in 40.4% of FDRs-BD, 31.5% of
FDRs-SZ, 12.6% of control subjects in the bipolar sample, and
9.0% of control subjects in the schizophrenia sample (Tables 1
and 2). Controlling for any diagnosis by adding affected status
(1 = yes/0 = no) as a covariate in the analysis did not change
the pattern of ﬁndings in either FDRs-BD or FDRs-SZ
(Supplemental Tables S9 and S10). Also, when comparing
only healthy relatives with healthy control subjects, the pattern
was similar (Supplemental Tables S11 and S12).
Effect of Age
Meta-regression analyses showed no relationship between
age and FDRs-BD effect sizes (Supplemental Table S13 and
Figure S2i–xvii). A positive relationship between age and
FDRs-SZ effect sizes reached nominal signiﬁcance only in the
amygdala (p = .008, which did not survive false discovery rate
correction for multiple comparisons) (Supplemental Table S13
and Figure S2i–xvii).
DISCUSSION
This ENIGMA-Relatives initiative allowed for the largest ex-
amination to date of FDRs-BD and FDRs-SZ. Through meta-
analysis, we investigated whether harmonized subcortical
and global brain measures differed between FDRs-BD and
FDRs-SZ and control subjects and whether these brainychiatry October 1, 2019; 86:545–556 www.sobp.org/journal 549
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Figure 1. (A) Cohen’s d effect sizes comparing
relatives and patients with bipolar disorder (BD)
(blue) and relatives and patients with schizophrenia
(SZ) (red) with control subjects for global brain
measures, (B) controlled for intracranial volume
(ICV). *Nominally signiﬁcant effect sizes (p , .05,
uncorrected); **q , .05, corrected.
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50 Yearsmeasures differed between the different relative types. The
main ﬁndings were that 1) FDRs-BD had larger ICVs, whereas
FDRs-SZ showed smaller thalamic volumes compared with
control subjects; 2) in FDRs-BD, ICV explained enlargements in
other brain measures, whereas in FDRs-SZ, brain volumes and
thickness became signiﬁcantly smaller than in control subjects
after correction for ICV; 3) abnormalities differed between the
relative types, but no clear pattern was detected; and 4) the
ﬁndings were not confounded by other psychiatric diagnoses
in the relatives and control subjects.
Effects in patients with schizophrenia and bipolar disorder
were in line with prior studies (4–12). In contrast to smaller
brain volumes in patients with bipolar disorder (7,8), we found
larger brain volumes in their relatives. This is in keeping with
other studies, which have reported larger regional gray matter
volumes in participants at genetic risk (16–26). As expected,
FDRs-SZ had smaller brain volumes, similar to ﬁndings in550 Biological Psychiatry October 1, 2019; 86:545–556 www.sobp.orgpatients with schizophrenia (6,10–12), but with smaller effect
sizes, in line with a previous retrospective meta-analysis and a
review (14,36). Effect sizes in both FDRs-SZ and FDRs-BD are
small (jdj # 0.16), suggesting that the brain abnormalities in
individuals at familial risk are subtle and can be detected only
with large sample sizes. These small effect sizes and potential
subtle differences could still be meaningful, as they may give
information on the familial background of brain deﬁcits in
disease. That said, it remains unclear whether brain deﬁcits
with these small effect sizes have functional or clinical rele-
vance for FDRs-BD and FDRs-SZ.
Bipolar disorder and schizophrenia have a partially over-
lapping genetic etiology, with a genetic correlation of rg =
0.60–0.68 based on population and genome-wide association
studies (1–3), suggesting that they share to some extent the
same risk genes. However, combined large genome-wide as-
sociation studies of schizophrenia and bipolar disorder have/journal
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Figure 2. (A) Cohen’s d effect sizes comparing relatives and patients with
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volume. *Nominally signiﬁcant effect sizes (p , .05, uncorrected); **q , .05,
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these disorders (37). That FDRs-BD and FDRs-SZ show
different global brain volume effects compared with control
subjects implies that these brain abnormalities are associated
with genetic variants unique to each disorder.
Twin studies have shown that schizophrenia (38–41) and
bipolar disorder (42,43) have a shared genetic origin for brain
volume, and overlapping brain abnormalities have been re-
ported between the two patient groups (4,5,9,13). However,
the available evidence for an association between common
variants in both schizophrenia and bipolar disorder and brain
volume is inconsistent (37,44–46). For example, Smeland et al.
(45) used novel conditional false discovery rate methodologyBiological Psand identiﬁed 6 shared loci between intracranial, hippocam-
pus, and putamen volumes and schizophrenia, whereas no
signiﬁcant genetic correlation was reported in another study
that applied standard statistical tools (44). Genetic risk for bi-
polar disorder was unrelated to the genetic variants associated
with brain measures (37,46). This could suggest either that rare
genetic variants, such as copy number variants that are shared
between relatives and probands, lead to brain abnormalities or
that nongenetic overlap, i.e., shared environmental factors,
leads to brain abnormalities in the family members.
The enlargement in several brain measures in FDRs-BD was
driven by a larger ICV, whereas the decrements in brain
measures in FDRs-SZ were more pronounced when controlling
for ICV. This suggests that in contrast to the global ICV ﬁnding
in FDRs-BD, brain abnormalities in FDRs-SZ not only are a
global effect but also represent more regional differences in
individuals at familial risk for schizophrenia. ICV reaches its
maximum size between the ages of 10 and 15 (47,48); there-
fore, ICV may be interpreted as a direct marker for neuro-
development. Indeed, both schizophrenia and bipolar disorder
have been characterized as neurodevelopmental disorders
(49–51); abnormal neurodevelopment may play a larger role in
the onset of schizophrenia than bipolar disorder (52–54). This
is in line with differential trajectories of IQ development and
school performance found in relation to risk for schizophrenia
and bipolar disorder, showing respectively poorer cognitive
performance or even decreases over time years before
schizophrenia onset and a U-shaped relationship between IQ
and later development of bipolar disorder (53). This is also in
keeping with a previous study, which found advanced brain
age relative to chronological age in participants in early stages
of schizophrenia, but not in participants in early stages of bi-
polar disorder (55). Given the discrepancy in ICV ﬁndings be-
tween FDRs-BD and FDRs-SZ, individuals at familial risk for
either bipolar disorder or schizophrenia may deviate during
early neurodevelopment in a disease-speciﬁc manner.
Interestingly, in contrast to FDRs-BD, patients with bipolar
disorder did not show an ICV enlargement, conﬁrming previous
ﬁndings in a large meta-analysis (7). In the early stages of the
disease, however, regional increases have been reported
(21,22,24,26,56,57). Given the positive relationship between
genetic risk for bipolar disorder and ICV reported in twins (13),
one could argue that the genetic liability for bipolar disorder
leads to a larger ICV as represented in our ﬁndings of larger
ICV in FDRs-BD. That combination of a genetic predisposition
for increased ICV and an ICV that is similar between patients
with bipolar disorder and control subjects may imply that pa-
tient ICV is decreased owing to illness-related factors. There-
fore, the discrepancy in ICV ﬁndings between patients with
bipolar disorder and their relatives might suggest that smaller
ICV in patients compared with their relatives can be regarded
as a (possibly prodromal) disease effect, similar to what has
been reported in schizophrenia. Alternatively, larger ICV in
FDRs-BD could represent a relative resilience to developing
bipolar disorder, as was suggested in a prior report on hip-
pocampal shape abnormalities in co-twins without bipolar
disorder (58).
The pattern and extent of brain abnormalities varied with
respect to the type of relationship to the proband. This again
suggests a role for environmental inﬂuences, as all FDRs shareychiatry October 1, 2019; 86:545–556 www.sobp.org/journal 551
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affected proband (except for monozygotic co-twins). Given
that many environmental risk factors, e.g., age, childhood
trauma, physical inactivity, and famine, are associated with
brain structure (59–61), environmental risk and/or gene-by-
environment interplay are likely also associated with differ-
ences in brain abnormalities in individuals at familial risk for
schizophrenia or bipolar disorder. However, despite the large
sample size, we did not ﬁnd a consistent pattern of abnor-
malities among different relative types. Power may still not be
sufﬁcient to detect these subtle differences. Alternatively, there
are many environmental factors that are unique for an
individual—and thus not speciﬁc to the relative type—and
these could have inﬂuenced brain structure.
Psychopathology is more prevalent in individuals at familial
risk for either bipolar disorder or schizophrenia than in the
general population; for example, offspring studies have shown
that 55% to 72% of individuals with a parent with bipolar
disorder or schizophrenia developed a lifetime mental disorder
(62,63). We showed that the presence of a psychiatric diag-
nosis in relatives and control subjects did not inﬂuence our
ﬁndings. This suggests that brain abnormalities seen in the
relatives represent the familial liability for the disorder and not
the presence of psychopathology.
Some limitations should be considered in interpreting the
results. This study is a meta-analysis of multiple cohorts from
research centers around the world, with heterogeneity across
samples (among others, acquisition protocols, ﬁeld strength,
FreeSurfer version, inclusion and exclusion criteria). Meta-
analysis will ﬁnd consistent effects despite this variance but
cannot remove all sources of heterogeneity. However, clinical
heterogeneity within and across sites is representative of the
broad, clinically varied, and ecologically valid nature of bipolar
disorder and schizophrenia and allows generalizable alterations
to be detected. One source of heterogeneity in the offspring in
particular might also be the substantial age differences between
the different offspring cohorts. Both adult and children/adoles-
cent offspring cohorts were included in the analyses, and the
fact that the brains of the child and adolescent offspring have not
reached adult size might have inﬂuenced the ﬁndings of the
overall offspring effects. In addition, inclusion criteria varied with
respect to psychopathology in FDRs or control subjects at the
different research centers. For example, some cohorts included
only healthy relatives, yet others included relatives with other
psychiatric diagnosis (except for having the disorder itself). We
accounted for this with additional analyses covarying for any
diagnosis or assessing only the healthy relatives. These ap-
proaches might not be sufﬁcient. In addition, the composition of
the FDRs-SZ and FDRs-BD groups differed. FDRs-SZ had a
greater sample size and consisted in particular of more siblings,
whereas there were more offspring in the FDRs-BD group.
Finally, the discrepancy in ICV between FDRs-BD and FDRs-SZ
may be associated with current IQ or parental socioeconomic
status (SES). Both IQ and parental SES have been associated
with brain structure (64–67). This might suggest that the larger
ICV found in FDRs-BD is related to higher IQ or parental SES.
Lower IQ has been reported in FDRs-SZ (68). However, the
literature regarding current IQ in individuals at familial risk for
bipolar disorder is less clear. Cognitive deﬁcits have been
associated with genetic risk for bipolar disorder (69,70). One552 Biological Psychiatry October 1, 2019; 86:545–556 www.sobp.orgstudy showed that siblings of patients with bipolar disorder had
lower IQ but that they did not differ on educational level
compared with control subjects (71). In contrast, a bipolar twin
study showed that both the proband and the co-twin without
bipolar disorder completed signiﬁcantly fewer years of education
than control twins (72). Furthermore, population studies show
that premorbid IQ or educational attainment are often not
affected or are even higher in individuals who later develop bi-
polar disorder (73–76), whereas IQ during childhood and
adolescence is lower in individuals who develop schizophrenia
later in life (77–82). The question remains how these measures
interact with brain development in individuals at familial risk. As
recently reported in a study that included only FDRs-SZ from one
site (Utrecht, The Netherlands), current IQ was intertwined with
most of the brain abnormalities (15). However, in FDRs-BD, it still
remains unclear how IQ and risk for bipolar disorder act on the
brain. In the current study, few cohorts had information available
on parental SES or subjects’ IQ, thereby excluding the possibility
to address these variables as potential confounders. Investi-
gating the inﬂuence of current IQ on the difference in brain
measures between relatives and control subjects was outside
the scope of this study, and we are collecting and harmonizing
these data from the cohorts for future analysis.
In conclusion, FDRs of patients with schizophrenia or bi-
polar disorder represent a group of individuals who can pro-
vide insight into the effect of familial risk on the brain. Although
liability for schizophrenia and bipolar disorder overlap in the
general populations, individuals at familial risk assessed here
showed a differential pattern of structural brain abnormalities.
This study found differences in brain abnormalities between
FDRs-SZ and FDRs-BD, in particular, a divergent effect in ICV.
This converse effect on ICV suggests that there may be
different neurodevelopmental trajectories for each disorder
early in life. Taken together, our ﬁndings may imply that brain
abnormalities in schizophrenia and bipolar disorder are due to
genetic variants or gene-by-environment interplay speciﬁc to
each disorder.
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